MDM2
46 programs · 45 companies
Programs
46
Companies
45
Active Trials
37
Targeting MDM2
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| LLY-6079 | Eli Lilly | Phase 2 | HSWilms | |
| LLY-3251 | Eli Lilly | Phase 2 | SCDNASH | |
| GSK-7987 | GSK | Phase 3 | MG | |
| AMG-2752 | Amgen | Preclinical | Heart FailureCRC | |
| REG-3155 | Regeneron | Phase 1/2 | Cervical CaMDD | |
| SRP-1135 | Sarepta | Phase 2/3 | Migraine | |
| ITO-535 | iTeos | NDA/BLA | PompeADPKD | |
| ALM-8546 | Alumis | Phase 1/2 | WilmsPTSD | |
| Motatinib | Protagonist | Preclinical | Bladder CaHCC | |
| Motacapivasertib | Grifols | NDA/BLA | RCCEpilepsy | |
| Miriderotide | Sobi | NDA/BLA | SchizophreniaRett | |
| Zorizumab | Sun Pharma | Phase 1 | Obesity | |
| BIO-3214 | BioArctic | Preclinical | IPF | |
| SAM-IIT-636 | Samsung Medical Ctr | NDA/BLA | AS | |
| CAM-IIT-608 | CAMS | Phase 1/2 | Urothelial Ca | |
| Pemizasiran | Scorpion | Phase 1/2 | DravetFSGS | |
| Rimatenlimab | Aera Ther | Phase 1/2 | CMLSCLC | |
| Rimacilimab | Atossa Therapeutics | Phase 2/3 | Prostate CaRB | |
| Doxafutibatinib | ProMIS Neurosciences | Phase 1 | MG | |
| Voxafotisoran | Turning Point (BMS) | Phase 2 | DLBCLNB | |
| Nirarasimod | Caladrius Bio | Phase 1/2 | OCD | |
| OBS-1037 | ObsEva (XOMA) | Preclinical | MDSFSGS | |
| IMV-1446 | IMV (renamed Immunovaccine) | Approved | CRC | |
| Voxasertib | Kamada | Phase 3 | Melanoma | |
| BIO-9035 | BioNova Pharma | Phase 2/3 | PVOCD | |
| Fixazasiran | OliX Pharma | Approved | Thymoma | |
| Bemaglumide | Prothena | Phase 3 | Prostate Ca | |
| DSG-6263 | Design Ther | Phase 1/2 | Breast Ca | |
| Polalemzoparlimab | Askbio (Bayer) | Phase 2/3 | RA | |
| Olpasertib | Applied DNA | Preclinical | LNRB | |
| 415-7410 | Kyowa Kirin | Phase 1 | PAH | |
| 618-7080 | CanSino | Phase 2 | NSCLCACC | |
| Motaratamab | Harbour BioMed | Phase 2/3 | MCLFL | |
| Talazanubrutinib | Scholar Rock | Phase 1/2 | MCCPNH | |
| Doxavorutinib | Genus | Preclinical | SMAMM | |
| REC-3246 | Recordati | Phase 2/3 | Breast Ca | |
| EXA-6597 | Exact Sciences | Phase 2/3 | Gastric Ca | |
| JUB-6434 | Jubilant Pharmova | Phase 1 | Heart FailurePompe | |
| TEC-5384 | Tecnoquimicas | NDA/BLA | IPF | |
| RIK-IIT-592 | RIKEN | Phase 1/2 | Parkinson's | |
| ASA-IIT-161 | Asan Medical Center | Phase 3 | Huntington's | |
| ROY-IIT-791 | Royal Marsden | Phase 2/3 | PTSD | |
| NAT-IIT-682 | National Univ Hospital | Approved | PsA | |
| Motanesiran | Lee's Pharm | Phase 2/3 | BCCRett | |
| Rimaratamab | Cybin | NDA/BLA | Obesity | |
| Kemacapivasertib | Polpharma | Phase 2/3 | IgANPompe |